https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-reata-pharmaceuticals
A recent acquisition by Biota of Reata for US$7billion dollars gives me comfort that our valuation may one day be in the same range. Reata has a drug of similar sales potential to PYC’s being about 5000 patients and a disease that is also lifelong. I have seen some comments from an analyst who covers both NEU and PYC that I will post in a minute if they are not in that article.
200m to AU10B is a 50 bagger.
If our revenue is a million in 3-4 years that would seem to be a reasonable value then. Larger companies looking at our company will be very interested in PYC, or individual assets once this tech is proven.And that could be early next year or even later this year. And we have the ability to generate multiple drugs over time…….each with a similar value.
It’s going to be an interesting 12 months as this plays out.
https://investors.biogen.com/news-releases/news-release-details/b...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.14 | $176.0K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3235 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 3592 | 8 |
View Market Depth
| Last trade - 15.37pm 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |